Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy in a Predominantly Non-Asian Population: RIVAL Results

Farooq, Amina; Frazier, Heather; Marcus, William B.; Fechter, Chelsea; Singh, Harinderjit; Marcus, Dennis M.

doi:10.3928/23258160-20161219-05

Cited by 3 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EVEREST II study found that combination therapy of full-dose PDT and intravitreal injections of ranibizumab was superior to monotherapy consisting of intravitreal injections of ranibizumab, in terms of BCVA and complete polyp regression [40]. However, recent studies suggest that anti-VEGF monotherapy with, for example, aflibercept has similar efficacy, at least in an Asian population [41,42].…”

Section: Specific Considerations When Treating Polypoidal Choroidal Vmentioning

confidence: 99%

Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach

et al. 2020

View full text Add to dashboard Cite

Photodynamic therapy (PDT) using verteporfin (VisudyneÒ; Bausch ? Lomb) is a treatment that is widely used to elicit cell and tissue death. In ophthalmology, PDT targets choroidal vascular abnormalities and induces selective occlusion of vessels. PDT was originally used in combination with full-dose verteporfin to treat neovascular age-related macular degeneration.Since the introduction of treatment with vascular endothelial growth factor receptor inhibitors, the clinical targets of PDT have shifted to other chorioretinal conditions, such as central serous chorioretinopathy, polypoidal choroidal vasculopathy, and choroidal hemangioma. In recent years, clinical studies have facilitated the optimization of treatment outcomes through changes in protocols, including the introduction of reduced treatment settings, such as PDT with half-dose verteporfin and half-fluence PDT. Here, we review PDT and its use for chorioretinal diseases from a practical perspective.Patients should be adequately informed to avoid direct sunlight after treatment, and side effects during and after PDT are rare.

show abstract

Section: Specific Considerations When Treating Polypoidal Choroidal Vmentioning

confidence: 99%

Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach

et al. 2020

View full text Add to dashboard Cite

show abstract

Retinal and Choroidal Vascular Diseases

Zhang

Grewal

2018

Current Practices in Ophthalmology

View full text Add to dashboard Cite

The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review

Wang

Shen

Cheng

et al. 2020

Journal of Ophthalmology

View full text Add to dashboard Cite

Topic. The aim of this study is to evaluate the efficacy of conbercept in PCV, which will optimize the management for PCV patients. Clinical Relevance. The use of antivascular endothelial growth factor (VEGF) therapy in polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration (nAMD), has been well established in randomized clinical trials. This meta-analysis has evaluated the efficacy of a novel anti-VEGF agent, conbercept, in the management of PCV using ranibizumab and aflibercept as the reference agents. Methods. Thirty studies with 1308 eyes were identified and included in this study. The primary outcome measures were best-corrected visual acuity (BCVA), and secondary outcomes were optical coherence tomography characteristics and polyp regression rates. The pooled results were calculated by the random-effect or fixed-effect model according to the heterogeneity of the data. Results. Despite a large standard deviation in means (SMD) improvement for BCVA and central retinal thickness (CRT) in the conbercept group, there was no statistically significant difference in the other outcomes compared to ranibizumab and aflibercept. However, there was a greater polyp regression rate in the conbercept group at 12 months. Conclusions. This systematic review indicates that conbercept may achieve similar BCVA and CRT improvements as ranibizumab and aflibercept, with a superior rate of polyp regression at 12 months.

show abstract

Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy in a Predominantly Non-Asian Population: RIVAL Results

Abstract: At 1 year, neovascular PCV in a predominantly non-Asian population treated with IAI demonstrated favorable visual, anatomic, and safety outcomes. [Ophthalmic Surg Lasers Imaging Retina. 2017;48:34-44.].

Cited by 3 publications

References 32 publications

Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach

Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach

Retinal and Choroidal Vascular Diseases

The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review

Contact Info

Product

Resources

About